Genprex, Inc.
GNPXDrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
How GNPX's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
quaratusugene ozeplasmid | Phase 2 | Carcinoma, Non-Small Cell Lung | - | - |
Frequently asked questions
What is in Genprex, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Genprex, Inc.'s (GNPX) pipeline across Phase 2. Its lead program is quaratusugene ozeplasmid (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Genprex, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Genprex, Inc. (GNPX) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track GNPX biotech catalysts?→
Add GNPX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Genprex, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.